IRIS
AMADORI, SERGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 87.035
EU - Europa 8.809
AS - Asia 8.130
SA - Sud America 1.155
AF - Africa 118
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 21
Totale 105.290
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 86.837
SG - Singapore 3.555
DE - Germania 2.819
CN - Cina 1.978
UA - Ucraina 1.225
RU - Federazione Russa 1.196
BR - Brasile 941
IT - Italia 813
HK - Hong Kong 781
IE - Irlanda 716
GB - Regno Unito 610
VN - Vietnam 590
FR - Francia 385
KR - Corea 376
FI - Finlandia 318
SE - Svezia 271
JP - Giappone 194
IN - India 126
PL - Polonia 119
CA - Canada 107
NL - Olanda 92
AR - Argentina 74
AT - Austria 60
ID - Indonesia 55
MX - Messico 55
BD - Bangladesh 53
TR - Turchia 51
IQ - Iraq 49
ES - Italia 43
ZA - Sudafrica 43
UZ - Uzbekistan 41
PH - Filippine 36
IR - Iran 34
PK - Pakistan 34
EC - Ecuador 31
BE - Belgio 29
CL - Cile 23
VE - Venezuela 22
CO - Colombia 21
SA - Arabia Saudita 20
AU - Australia 18
CZ - Repubblica Ceca 18
MY - Malesia 18
EG - Egitto 17
PE - Perù 16
PY - Paraguay 16
CH - Svizzera 15
JO - Giordania 15
EU - Europa 13
IL - Israele 13
TH - Thailandia 13
TW - Taiwan 13
MA - Marocco 12
LB - Libano 11
LT - Lituania 10
DK - Danimarca 9
GR - Grecia 9
NP - Nepal 9
PT - Portogallo 9
TN - Tunisia 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
NO - Norvegia 8
SN - Senegal 8
AL - Albania 7
CY - Cipro 7
KE - Kenya 7
KG - Kirghizistan 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
RO - Romania 6
HU - Ungheria 5
LA - Repubblica Popolare Democratica del Laos 5
PA - Panama 5
AO - Angola 4
AZ - Azerbaigian 4
BH - Bahrain 4
DM - Dominica 4
HN - Honduras 4
JM - Giamaica 4
KZ - Kazakistan 4
NG - Nigeria 4
OM - Oman 4
PS - Palestinian Territory 4
QA - Qatar 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
CR - Costa Rica 3
GE - Georgia 3
GT - Guatemala 3
LK - Sri Lanka 3
A1 - Anonimo 2
AM - Armenia 2
BO - Bolivia 2
BY - Bielorussia 2
ET - Etiopia 2
HR - Croazia 2
MD - Moldavia 2
MK - Macedonia 2
Totale 105.264
Salva come PNG Salva come JPEG
Città #
Woodbridge 26.935
Wilmington 22.019
Houston 18.859
Fairfield 2.502
Ann Arbor 2.124
Singapore 1.990
Ashburn 1.573
Chandler 1.365
Jacksonville 1.121
Seattle 1.063
San Jose 882
Cambridge 843
Dearborn 766
Hong Kong 762
Beijing 720
Dublin 696
Medford 546
New York 392
Santa Clara 344
The Dalles 313
Zhengzhou 298
Lawrence 256
Dallas 249
Los Angeles 234
Rome 214
Ho Chi Minh City 193
Mülheim 157
Moscow 150
Tokyo 147
Buffalo 145
Hanoi 126
Lauterbourg 120
San Diego 118
Council Bluffs 106
São Paulo 95
Menlo Park 86
Munich 85
Milan 83
Shanghai 77
London 73
Boardman 72
Kraków 67
Falls Church 64
Helsinki 63
Creede 55
Hefei 55
Guangzhou 54
Nuremberg 51
Redwood City 51
Chicago 50
Nanjing 50
Norwalk 50
Orem 48
University Park 48
Mountain View 43
Columbus 40
Warsaw 40
Brooklyn 38
Montreal 38
Phoenix 38
Kunming 37
Redondo Beach 36
San Mateo 36
Rio de Janeiro 35
Frankfurt am Main 33
Palo Alto 32
Denver 30
Nürnberg 30
Verona 30
Atlanta 28
Chennai 28
Da Nang 28
Johannesburg 27
Toronto 27
Hangzhou 26
San Francisco 26
Bologna 25
Saint Petersburg 25
Amsterdam 24
Brussels 24
Jakarta 24
Vienna 23
Haiphong 21
North Bergen 20
Porto Alegre 19
Mumbai 18
Poplar 18
Stockholm 18
Belo Horizonte 17
Nanchang 17
Florence 16
Boston 15
Jinan 15
Kilburn 15
Manchester 15
Mexico City 15
Seoul 15
Shenyang 15
New Delhi 14
Auburn Hills 13
Totale 90.772
Salva come PNG Salva come JPEG
Nome #
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 667
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 661
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 627
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel 547
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 542
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 540
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 532
6-phosphogluconate dehydrogenase deficiency in an Italian family 516
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 516
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy 512
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 512
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas 511
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 507
Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators 506
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 504
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 504
Acute foetal distress and umbilical cord blood banking 497
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 497
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study 496
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 496
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 494
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 494
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 489
High expression levels of vla-4 (CD49d) on mobilised peripheral blood stem cells are associated with rapid engraftment in multiple myeloma patients receiving autologous transplant 486
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia final results of AML-13, a randomized phase-3 study 485
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 484
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 482
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia 480
Use of arsenic trioxide in haematological malignancies: Insight into the clinical development of a novel agent 480
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia 480
Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura 477
Treatment of multiple myeloma: A randomized study of three different regimens 477
Clinical significance of CD38 expression in chronic lymphocytic leukemia 476
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 475
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 474
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 473
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 472
A new system for quality control in hematopoietic progenitor cell units before reinfusion in autologous transplant 472
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice 471
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 470
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 470
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 470
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 469
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 469
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 467
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults 465
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 464
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 464
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 463
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 462
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 462
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 461
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 461
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 460
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 460
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 460
Biological features of acute myeloid leukemia in the elderly 460
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia 460
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 459
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 457
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 457
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience 455
Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab 455
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura 454
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 452
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 452
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 450
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 448
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia 447
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 447
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study 446
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse 446
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 446
Placental/Umbilical cord blood: experience of St. Eugenio Hospital collection center 446
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant 446
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 445
AML-M0: a biological and clinical profile 445
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 445
Induction of Apoptosis by Pyrrolobenzothiadiazepines (PBTDs) in cell lines and in 12 chronic myeloid leukaemia patients and imatinib-resistant 443
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. 443
Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes 442
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 442
Unrelated Cord Blood transplantaion for children with high risk myelodysplastic syndrome 440
Biological pattern of AML-M0 versus AML-M1: Response 440
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab 439
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 439
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION 439
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 439
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 438
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825 438
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 438
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 438
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. 437
FISH analysis for CML monitoring? 436
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 436
Sequential administration of gemtuzubab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-15A phase II trial 435
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients 435
Recurrence of a t(8;21)-positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge 433
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. 432
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 432
Totale 47.260
Salva come PNG Salva come JPEG
Categoria #
all - tutte 217.359
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 217.359
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021729 0 0 0 0 0 0 0 0 0 0 553 176
2021/20222.543 90 288 104 124 72 249 134 131 141 260 149 801
2022/20233.603 402 249 210 408 280 757 336 211 399 31 243 77
2023/20241.207 139 41 62 29 146 401 86 44 15 20 23 201
2024/20255.657 213 1.374 679 301 96 239 445 285 501 450 507 567
2025/20268.246 771 428 1.178 678 723 336 1.038 1.038 1.142 906 8 0
Totale 105.750